Temafloxacin

	WikiDoc Resources for Temafloxacin
Articles
Most recent articles on Temafloxacin Most cited articles on Temafloxacin Review articles on Temafloxacin Articles on Temafloxacin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Temafloxacin Images of Temafloxacin Photos of Temafloxacin Podcasts & MP3s on Temafloxacin Videos on Temafloxacin
Evidence Based Medicine
Cochrane Collaboration on Temafloxacin Bandolier on Temafloxacin TRIP on Temafloxacin
Clinical Trials
Ongoing Trials on Temafloxacin at Clinical Trials.gov Trial results on Temafloxacin Clinical Trials on Temafloxacin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Temafloxacin NICE Guidance on Temafloxacin NHS PRODIGY Guidance FDA on Temafloxacin CDC on Temafloxacin
Books
Books on Temafloxacin
News
Temafloxacin in the news Be alerted to news on Temafloxacin News trends on Temafloxacin
Commentary
Blogs on Temafloxacin
Definitions
Definitions of Temafloxacin
Patient Resources / Community
Patient resources on Temafloxacin Discussion groups on Temafloxacin Patient Handouts on Temafloxacin Directions to Hospitals Treating Temafloxacin Risk calculators and risk factors for Temafloxacin
Healthcare Provider Resources
Symptoms of Temafloxacin Causes & Risk Factors for Temafloxacin Diagnostic studies for Temafloxacin Treatment of Temafloxacin
Continuing Medical Education (CME)
CME Programs on Temafloxacin
International
Temafloxacin en Espanol Temafloxacin en Francais
Business
Temafloxacin in the Marketplace Patents on Temafloxacin
Experimental / Informatics
List of terms related to Temafloxacin

Temafloxacin
Clinical data
Routes of; administration	Oral
ATC code	J01MA05 (WHO) ;
Legal status
Legal status	Withdrawn;
Identifiers
	IUPAC name 1-(2,4-Difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;
PubChem CID	60021;
DrugBank	DB01405 ;
ChemSpider	54143 ;
UNII	1WZ12GTT67;
KEGG	D02469 ;
ChEBI	CHEBI:77788 ;
ChEMBL	ChEMBL277100 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C21H18F3N3O3
Molar mass	417.381 g/mol
3D model (JSmol)	Interactive image;
	SMILES Fc1ccc(c(F)c1)N\3c2cc(c(F)cc2C(=O)C(/C(=O)O)=C/3)N4CC(NCC4)C;
	InChI InChI=1S/C21H18F3N3O3/c1-11-9-26(5-4-25-11)19-8-18-13(7-16(19)24)20(28)14(21(29)30)10-27(18)17-3-2-12(22)6-15(17)23/h2-3,6-8,10-11,25H,4-5,9H2,1H3,(H,29,30) ; Key:QKDHBVNJCZBTMR-UHFFFAOYSA-N ;
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Temafloxacin (marketed by Abbott Laboratories as Omniflox) is a fluoroquinolone antibiotic drug which was withdrawn from sale in the United States shortly after its approval in 1992 because of serious adverse effects resulting in three deaths.^[1]^[2]

History

Omniflox was approved to treat lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections in the United States by the Food and Drug Administration in January 1992. Severe adverse reactions, including allergic reactions and hemolytic anemia,^[3] developed in about fifty patients during the first four months of its use, leading to three patient deaths. Abbott withdrew the drug from sale in June 1992.

Pharmacokinetic

Following oral administration the compound is well absorbed from the gastrointestinal tract. The oral bioavailability is greater than 90%. Temafloxacin has a good tissue penetration in various biological fluids and tissues, particularly in the respiratory tissues, nasal secretions, tonsils, prostate and bone.^[4] In these districts the concentrations achieved are equal to or higher than those in serum.^[5] The fluoroquinolone has a 7-8 hour half-life.^[6] The penetration into the central nervous system (CNS)is less pronounced.^[6]The escretion from the body is primarily due to the glomerular filtration.^[7]^[8]^[9]

Clinical uses

The compound is indicated for treating lower respiratory tract infections (community-acquired pneumonia, exacerbations of chronic bronchitis), genital and urinary tract infections (prostatitis, gonococcal and non-gonococcal urethritis, cervicitis), skin and soft tissue infections.^[6]^[10]^[11]^[12]

References

↑ "Recalling the Omniﬂox (Temaﬂoxacin) Tablets" (pdf). Food and Drug Administration. 1992-06-05. Retrieved 2014-10-15.
↑ "ABBOTT WITHDRAWS TEMAFLOXACIN - Pharmaceutical industry news". The Pharmaletter. 1992-06-15. Retrieved 2014-10-16.
↑ Rubinstein, E. (2001). "History of quinolones and their side effects". Chemotherapy. 47 Suppl 3: 3–8, discussion 44–8. doi:10.1159/000057838. PMID 11549783.
↑ Sorgel F, Naber KG, Kinzig M, Mahr G, Muth P (December 1991). "Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review". Am. J. Med. 91 (6A): 51S–66S. PMID 1662896. |access-date= requires |url= (help)
↑ Sörgel F (1992). "Penetration of temafloxacin into body tissues and fluids". Clin Pharmacokinet. 22 Suppl 1: 57–63. doi:10.2165/00003088-199200221-00010. PMID 1319872. |access-date= requires |url= (help)
↑ ^6.0 ^6.1 ^6.2 Pankey GA (December 1991). "Temafloxacin: an overview". Am. J. Med. 91 (6A): 166S–172S. PMID 1662889. |access-date= requires |url= (help)
↑ Granneman GR, Carpentier P, Morrison PJ, Pernet AG (February 1992). "Pharmacokinetics of temafloxacin in humans after multiple oral doses". Antimicrob. Agents Chemother. 36 (2): 378–86. doi:10.1128/aac.36.2.378. PMC 188445. PMID 1318680. Retrieved 2014-10-17.
↑ Granneman GR, Braeckman R, Kraut J, Shupien S, Craft JC (November 1991). "Temafloxacin pharmacokinetics in subjects with normal and impaired renal function". Antimicrob. Agents Chemother. 35 (11): 2345–51. doi:10.1128/aac.35.11.2345. PMC 245383. PMID 1666497. Retrieved 2014-10-17.
↑ Dudley MN (December 1991). "A review of the pharmacokinetic profile of temafloxacin". J. Antimicrob. Chemother. 28 Suppl C: 55–64. doi:10.1093/jac/28.suppl_c.55. PMID 1664830. Retrieved 2014-10-17.
↑ Gentry LO (December 1991). "Review of quinolones in the treatment of infections of the skin and skin structure". J. Antimicrob. Chemother. 28 Suppl C: 97–110. PMID 1787128. Retrieved 2014-10-17.
↑ Wise R (December 1991). "Comparative penetration of selected fluoroquinolones into respiratory tract fluids and tissues". Am. J. Med. 91 (6A): 67S–70S. PMID 1662897. |access-date= requires |url= (help)
↑ Symonds WT, Nix DE (September 1992). "Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials". Clin Pharm. 11 (9): 753–66. PMID 1325892. |access-date= requires |url= (help)

External links

FDA press release June 5, 1992.^{[dead link]}

Template:QuinoloneAntiBiotics

[urlwww.fda.gov-1] "Recalling the Omniﬂox (Temaﬂoxacin) Tablets" (pdf). Food and Drug Administration. 1992-06-05. Retrieved 2014-10-15.

[ABBOTT_WITHDRAWS_TEMAFLOXACIN-2] "ABBOTT WITHDRAWS TEMAFLOXACIN - Pharmaceutical industry news". The Pharmaletter. 1992-06-15. Retrieved 2014-10-16.

[3] Rubinstein, E. (2001). "History of quinolones and their side effects". Chemotherapy. 47 Suppl 3: 3–8, discussion 44–8. doi:10.1159/000057838. PMID 11549783.

[pmid1662896-4] Sorgel F, Naber KG, Kinzig M, Mahr G, Muth P (December 1991). "Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review". Am. J. Med. 91 (6A): 51S–66S. PMID 1662896. |access-date= requires |url= (help)

[pmid1319872-5] Sörgel F (1992). "Penetration of temafloxacin into body tissues and fluids". Clin Pharmacokinet. 22 Suppl 1: 57–63. doi:10.2165/00003088-199200221-00010. PMID 1319872. |access-date= requires |url= (help)

[pmid1662889-6] 6.0 ^6.1 ^6.2 Pankey GA (December 1991). "Temafloxacin: an overview". Am. J. Med. 91 (6A): 166S–172S. PMID 1662889. |access-date= requires |url= (help)

[pmid1318680-7] Granneman GR, Carpentier P, Morrison PJ, Pernet AG (February 1992). "Pharmacokinetics of temafloxacin in humans after multiple oral doses". Antimicrob. Agents Chemother. 36 (2): 378–86. doi:10.1128/aac.36.2.378. PMC 188445. PMID 1318680. Retrieved 2014-10-17.

[pmid1666497-8] Granneman GR, Braeckman R, Kraut J, Shupien S, Craft JC (November 1991). "Temafloxacin pharmacokinetics in subjects with normal and impaired renal function". Antimicrob. Agents Chemother. 35 (11): 2345–51. doi:10.1128/aac.35.11.2345. PMC 245383. PMID 1666497. Retrieved 2014-10-17.

[pmid1664830-9] Dudley MN (December 1991). "A review of the pharmacokinetic profile of temafloxacin". J. Antimicrob. Chemother. 28 Suppl C: 55–64. doi:10.1093/jac/28.suppl_c.55. PMID 1664830. Retrieved 2014-10-17.

[pmid1787128-10] Gentry LO (December 1991). "Review of quinolones in the treatment of infections of the skin and skin structure". J. Antimicrob. Chemother. 28 Suppl C: 97–110. PMID 1787128. Retrieved 2014-10-17.

[pmid1662897-11] Wise R (December 1991). "Comparative penetration of selected fluoroquinolones into respiratory tract fluids and tissues". Am. J. Med. 91 (6A): 67S–70S. PMID 1662897. |access-date= requires |url= (help)

[pmid1325892-12] Symonds WT, Nix DE (September 1992). "Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials". Clin Pharm. 11 (9): 753–66. PMID 1325892. |access-date= requires |url= (help)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]